Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
NCT ID: NCT00322036
Last Updated: 2008-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
800 participants
INTERVENTIONAL
2006-05-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Oral 800 mg BID dosing
MPC-7869
Oral 800 mg BID
2
Oral BID dosing
MPC-7869
Oral BID dosing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MPC-7869
Oral 800 mg BID
MPC-7869
Oral BID dosing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Men or women ages greater than or equal to 55 years and living in the community at the time of enrollment (ie, not living in a rest home or nursing care facility).
3. Signed the subject Informed Consent Form (ICF) and is willing and able to participate for the duration of the study.
4. Ability to read and understand English, Dutch, Danish, Flemish, French, German, Italian, Spanish or Swedish to ensure compliance with cognitive testing and study visit procedures.
5. At least 6 years of education, or sufficient work history to exclude mental retardation.
6. Female subjects must be surgically sterile or postmenopausal for \> 1 year.
7. Adequate vision and hearing to participate in study assessments.
8. Subjects must have a reliable caregiver who can read, understand and speak same language.
Exclusion Criteria
2. History of, or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor.
3. Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.
4. Major surgery and related complications not resolved within 12 weeks prior to Day 1.
5. Previous participation in an MPC-7869 clinical study.
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Myrexis Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Myriad Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Laughlin, MD
Role: STUDY_DIRECTOR
Myrexis Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix, Arizona, United States
Tucson, Arizona, United States
Costa Mesa, California, United States
San Diego, California, United States
New Haven, Connecticut, United States
Deerfield Beach, Florida, United States
Delray Beach, Florida, United States
Gainsville, Florida, United States
Hollywood, Florida, United States
Miami, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Lexington, Kentucky, United States
Boston, Massachusetts, United States
Farmington Hills, Michigan, United States
St Louis, Missouri, United States
Rochester, New York, United States
Providence, Rhode Island, United States
Charleston, South Carolina, United States
Dallas, Texas, United States
Salt Lake City, Utah, United States
Aalst, , Belgium
Antwerp, , Belgium
Edegem, , Belgium
Hasselt, , Belgium
Leuven, , Belgium
Sint-Truiden, , Belgium
Calgary, Alberta, Canada
Medicine Hat, Alberta, Canada
Vancouver, British Columbia, Canada
Winnipeg, Manitoba, Canada
Moncton, New Brunswick, Canada
Saint John, New Brunswick, Canada
Halifax, Nova Scotia, Canada
Kingston, Ontario, Canada
London, Ontario, Canada
Ottawa, Ontario, Canada
Peterborough, Ontario, Canada
Toronto, Ontario, Canada
Greenfield Park, Quebec, Canada
Montreal, Quebec, Canada
Verdun, Quebec, Canada
Regina, Saskatchewan, Canada
Odense, , Denmark
Odense C, , Denmark
Bordeaux, , France
Dijon, , France
Marseille, , France
Montpellier, , France
Nice, , France
Reims, , France
Rennes, , France
Saint-Herblain, , France
Toulouse, , France
Tours, , France
Berlin, , Germany
Bochum, , Germany
Bonn, , Germany
Darmstadt, , Germany
Düsseldorf, , Germany
Freiburg im Breisgau, , Germany
Hamburg, , Germany
Heidelberg, , Germany
Leipzig, , Germany
Mannheim, , Germany
München, , Germany
Schwerin, , Germany
Brescia, , Italy
Milan, , Italy
Perugia, , Italy
Pisa, , Italy
Roma, , Italy
's-Hertogenbosch, , Netherlands
Amsterdam, , Netherlands
Blaricum, , Netherlands
Barcelona, , Spain
Bilbao, , Spain
Getafe. Madrid, , Spain
Madrid, , Spain
Lund, , Sweden
Basel, , Switzerland
Bath, England, United Kingdom
London, England, United Kingdom
Oxford, England, United Kingdom
Sheffield, England, United Kingdom
Swindon, England, United Kingdom
Belfast, Northern Ireland, United Kingdom
Glasgow, Scotland, United Kingdom
Penarth, Wales, United Kingdom
Southhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MPC-7869-05-010.01
Identifier Type: -
Identifier Source: org_study_id